Legal Representation
Attorney
Sheila R. Gibson
USPTO Deadlines
Next Deadline
1583 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-12-05)
Due Date
December 05, 2029
Grace Period Ends
June 05, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
13 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 5, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 5, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Sep 19, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 19, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 30, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 10, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 10, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 10, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 10, 2023 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 10, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 7, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 7, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 27, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
scientific research in the field of oncology; scientific research in the field of immuo-dysregulated diseases; development of pharmaceutical preparations and medicines for the treatment of cancer; development of pharmaceutical preparations and medicines for the treatment of immuno-dysregulated diseases; clinical research in the field of oncology; clinical research in the field of immuo-dysregulated diseases; research and development services in the field of anti-cancer preparations; research and development services in the field of preparations for treating immuno-dysregulated diseases; pharmaceutical drug design, product engineering, pharmaceutical research, pharmaceutical drug development and pharmaceutical product quality testing services for others in the field of oncology; pharmaceutical drug design, product engineering, pharmaceutical research, pharmaceutical drug development and pharmaceutical product quality testing services for others in the field of immuno-dysregulated diseases; providing information regarding medical research relating to oncology; providing information regarding medical research relating to immuno-dysregulated diseases
First Use Anywhere:
Dec 31, 2012
First Use in Commerce:
Oct 15, 2013
Class 044
providing medical information about the treatment of cancer; providing medical information about the treatment of immuno-dysregulated diseases; providing a website featuring healthcare and medical information, namely, information about cancer and the treatment of cancer; providing a website featuring healthcare and medical information, namely, information about immuno-dysregulated diseases and the treatment of immuno-dysregulated diseases
First Use Anywhere:
Dec 31, 2012
First Use in Commerce:
Oct 15, 2013
Classification
International Classes
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOPHARMA"